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Abstract
The molecular technology known as clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated protein
(Cas) is revolutionizing the field of medical research and deepening our understanding of numerous biological processes. The
attraction of CRISPR/Cas9 lies in its ability to efficiently edit DNA or modulate gene expression in living eukaryotic cells and
organisms, a technology that was once considered either too expensive or scientifically risky. CRISPR/Cas9 has been success-
fully applied in agriculture to develop the next generation of disease-resistant plants. Now, the capability of gene editing has been
translated to the biomedical area, focusing on the future of medicine faced with drug-resistant microbes by selectively targeting
genes involved in antibiotic resistance, for example, or finding the ultimate strategy for cancer or HIV. In this regard, it was
recently demonstrated that an injection of cancer-fighting CRISPR-modified white blood cells in a patient suffering from
metastatic lung cancer could lead to promising results. Researchers and bioethicists are debating questions about the regulation
of CRISPR/Cas9 that must be addressed. While legal challenges surround the use of this technique for genetically modifying cell
lines in humans, we review the basic understanding of CRISPR/Cas9 and discuss how this technology could represent a
candidate for treatment of non-communicable diseases in nutrition, such as obesity.
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Obesity
Obesity is a health issue characterized by abnormal or excessive 
fat accumulation and increased body mass index (BMI), which 
is an index of weight to height commonly used to classify obe-
sity. This parameter is defined as a person’s weight in kilograms 
divided by the square of their height in meters (kg/m2), with 
obesity classified as a BMI of 30 or greater (Hruby and Hu 
2015). Obesity has been shown to cause additional health prob-
lems including heart disease, hypertension, type 2 diabetes, and 
cancer (Hemminki et al. 2011; Laitala et al. 2011), suggesting 
the importance of the study of this disorder, as well as the de-
velopment of approaches for its prevention and management.
Obesity has become a worldwide health problem, with in-
creasing prevalence globally over the past few decades.
Among the world’s population in 2008, for example, 10% of
men and 14% of women were obese, compared with 5% of
men and 8% of women in 1980 (World Health Organization
2015); in 2012, more than 40million children under the age of
5 were overweight or obese (World Health Organization
2016).
The etiology of obesity is complex, since it involves a
number of factors that interact in ways that are not well un-
derstood. Among these variables, socioeconomic status, ge-
netics, cultural aspects, and lifestyle have been reported as
critical elements in the genesis of obesity (Barclay et al.
2015; Borghese et al. 2015; Gervasini and Gamero-
Villarroel 2015; Mayans 2015; Smith and Ryckman 2015).
Despite its multifactorial nature, a general consensus has
emerged that obesity is the result of an energy imbalance
and the promotion of excessive fat deposition (Herrera and
Lindgren 2010; Kuntz and Lampert 2010; Merchant et al.
2009; Singla et al. 2010; Wiwanitkit 2012; World Health
Organization 2016). Understanding the role of the above-
mentioned factors in the genesis of obesity is further compli-
cated by the impacts that certain food marketing practices and
institutionally driven physical activity reductions have in trig-
gering the development of obesity. In this regard, variables
such as increased portion sizes in commerciallymarketed food
items, the ubiquitous presence of inexpensive but unhealthy
food sources such as fast food, the availability of vending
machines with energy-dense items, the promotion of high-
fructose corn syrup (HFCS), and the reduction in physical
education in schools have been described as interacting to
favor to the development of obesity (Bocarsly et al. 2010;
Klurfeld et al. 2013; Stanhope et al. 2011). In addition, neu-
rochemical influences have been documented in obesity. For
example, diverse compounds such as peptides (ghrelin,
orexin, neuropeptide Y, vasoactive intestinal peptide, chole-
cystokinin), hormones (melanin-concentrating hormone, lep-
tin), and lipids are associated with obesity (Geibel et al. 2014;
Igarashi et al. 2015; Liu et al. 2010; Mallipedhi et al. 2015;
Monteleone et al. 2016; Steiner et al. 2013; Wali et al. 2014;
Warchol et al. 2014; Zhang et al. 2014). Moreover, obese
individuals face a Bdouble burden^ of disease, since the dis-
ease causes additional health problems, including diabetes,
hypertension, dyslipidemia, cardiovascular diseases, fatty liv-
er disease, cancer, musculoskeletal disorders, breathing diffi-
culties, risk of fractures, and psychological effects (Mollard
et al. 2014; Papakonstantinou et al. 2013; Vucenik and Stains
2012). Thus one can assume that the obese population will
eventually experience multiple different health-related issues.
Current Therapeutic Approaches
for Managing Obesity
There are several therapeutic alternatives with positive out-
comes for managing obesity (Higuera-Hernández et al.
2018; Igel et al. 2017). Among current strategies, pharmaco-
logical treatments including canagliflozin and metformin have
been described (Arafa et al. 2016; Martinussen et al. 2017;
Razavi and Hosseinzadeh 2017; Zimbron et al. 2016).
Cognitive behavioral therapy has also shown positive results,
while surgical procedures such as sleeve gastrectomy, gastric
bypass, gastric banding, and duodenal switch are the most
common bariatric approaches aimed at managing obesity
(Gero et al. 2017; Hanipah and Schauer 2017; Kaplan 2017;
Zimbron et al. 2016). One noninvasive non-pharmacological
intervention is exercise (Bruyndonckx et al. 2015; Carter et al.
2015; Glynn et al. 2015). However, it has been demonstrated
that many patients are still unable to achieve a clinicallymean-
ingful improvement, since their principal motivation is based
on a better appearance rather than improving their health sta-
tus. Thus, novel therapeutic strategies are needed for obesity
interventions.
Obesity as Genetic Susceptibility to Weight
Gain
More than 200 common genetic variants have been found to
be associated with obesity, which has generated research in-
terest in the development of unique, personalized preventive
or treatment strategies (Garver et al. 2013; Loos and Janssens
2017; Manco and Dallapiccola 2012; Ng and Bowden 2013).
In this regard, it has been described that obesity is due to rare
mutations in single genes or chromosomal abnormalities
(Chung 2012; Manco and Dallapiccola 2012; Ng and
Bowden 2013; Pigeyre et al. 2016; Romieu et al. 2017). In
most of the obese population, multifactorial and polygenic
variants are likely responsible for the development of this
disease. Several large-scale studies have examined the ability
of genome-wide association study (GWAS)-identified BMI-
associated loci to predict adult obesity (Belsky et al. 2013;
Hung et al. 2015; Li et al. 2010; Locke et al. 2015; Peterson
et al. 2011; Sandholt et al. 2010; Speliotes et al. 2010). For
instance, eight monogenic genes and four polygenic genes
(FTO, PCSK1, MC4R, CTNNBL1) from GWAS have been
associated with obesity, and several loci have been recognized
to be involved in Mendelian forms of obesity. An elegant
review of this topic is provided by Choquet andMeyre (2011).
Notwithstanding these fascinating findings, the use of
existing and novel technologies would allow us to prevent,
rather than predict, obesity by gene editing. The importance
of identifying obesity-related genes is in the predictive value
of such an approach, enabling the initiation of preventive
treatment in those patients determined to be at risk. For in-
stance, three risk-prediction models were examined, with each
consecutive model including a higher number of BMI-
associated loci, which allowed for the assessment of whether
adding more loci would improve prediction. By using previ-
ous data from the population-based EPIC-Norfolk study, the
models aimed to predict obesity compared to normal weight.
The fat mass and obesity-associated (FTO) locus was the first
GWAS-identified obesity locus (Li et al. 2010). More impor-
tantly, polymorphisms in the FTO gene region in obese
patients have been identified in multiple populations, suggest-
ing thatFTOwould be the first locus unequivocally associated
with adiposity (Fawcett and Barroso 2010). We highlight the
importance of recognizing that different forms of obesity may
result, unlike genetic and non-genetic risk factors (Aarestrup
et al. 2016; Loos and Janssens 2017; Whitaker et al. 1997).
Thus, separate therapeutic approaches are needed for different
forms of obesity with dissimilar origins, such as monogenic
early-onset obesity. In this regard, gene editing has been an
important method for studying the function of genes, and may
offer a promising new perspective in the treatment of obesity.
CRISPR/Cas9 Gene Editing Technology
Streptococcus thermophilus is widely used in the dairy indus-
try for production of yogurt and cheese (Delorme 2008).
Scientists at Danisco explored how the bacteria responded to
phage attack, a common problem in industrial yogurt making.
Interestingly, Barrangou and coworkers (Barrangou et al.
2007) experimentally showed that a new technique acted as
an adaptive immune system, since the authors were able to
integrate new phage DNA into the new molecular array,
allowing them to fight off the next wave of attacking phage.
This novel technology, which was given the name Bclustered
regularly interspaced palindromic repeats (CRISPR)/
CRISPR-associated protein (Cas),^ enabled editing of parts
of the genome by removing, adding, or altering sections of
the DNA sequence (Ding et al. 2016; Lander 2016; Ledford
2016; Nelles et al. 2015).
Given this new technique, it is tempting to consider that
several illnesses might be treated by gene editing. In fact,
researchers in China investigated whether mutations in the
β-globin gene could be corrected in human embryos (Liang
et al. 2015). Another potential use of the CRISPR/Cas9 sys-
tem might be the elimination of malaria by gene editing
(Gabrieli et al. 2014). The putative medical uses of CRISPR/
Cas9 have been reported as well (Harper 2017; Kehler et al.
2017; Pope 2017; Wang et al. 2017; Zulfiqar et al. 2017),
including in obesity (Ackermann et al. 2017; Bao et al.
2015; Lu et al. 2017; Xia et al. 2016). However, several ethical
issues have been raised concerning the potential use of
CRISPR/Cas9 in health issues (Mulvihill et al. 2017). Since
CRISPR/Cas9 has been successfully harnessed for genome
editing (Cong et al. 2013; Mali et al. 2013), it is critical to
consider testing this molecular technology in obesity.
CRISPR/Cas9 as a Promising Tool for Treating
Obesity
CRISPR/Cas9 approaches could be utilized to unlock novel
insights into obesity research. However, the field has yet to
capitalize upon the technology. Although this review provides
speculative rather than insightful propositions, CRISPR/Cas9
technology will in time revolutionize our understanding of the
genetic mechanisms in several neurobiological functions as
well as in pathologies such as obesity, among many others,
by investigating CRISPR/Cas9 gene editing in obese experi-
mental models (e.g., Carroll 2016; Heidenreich and Zhang
2015). It will be possible to explore neuromolecular mecha-
nisms associated with obesity that were not possible just a few
years ago. Since there are several genes that appear to be
associated with obesity, one could assume that even 2–3 years
from now, there will be substantial literature showing how the
new gene editing technologies have enabled testing of specific
hypotheses with regard to treating obesity (Fig. 1).
Claussnitzer et al. (2015) recently reported that CRISPR/
Cas9 editing of the rs1421085 T-to-C single-nucleotide vari-
ant in adipocytes from patient activated browning expression
and restored thermogenesis. Preliminary but significant ad-
vances have been achieved using CRISPR/Cas9 technology
in fat mass and obesity (Walters et al. 2017). For example, a
potential connection has been suggested between the
CRISPR/Cas9 fingerprint and obesity based on an existing
chemical-gene-disease database (Xia et al. 2016). Along these
lines, Roh et al. (2018) have generated the first CRISPR/Cas9-
induced leptin and leptin receptor gene knockout mouse mod-
el. These experimental animal models have shown phenotypic
obesity-related characteristics including enhanced body
weight, hyperglycemia, and hepatic steatosis. Although still
in the early stages, CRISPR/Cas9 technologymay be a critical
tool for managing obesity in humans in the near future.
Editing Genes for Obesity…or for Addiction?
Indeed, obesity is a multifactorial and polygenic disease (Loos
and Janssens 2017). However, further complexity is intro-
duced in that obesity is linked with compulsive eating behav-
iors (Moore et al. 2017a). The construct of food addiction
provides a framework within which to consider the genesis
and management of obesity from a different perspective.
Current opinions propose that, rather than a metabolic disease,
obesity might be the consequence of addictive tendencies to-
ward food (Moore et al., 2017b), and novel theories of obesity
as a food addiction issue have been suggested (Hebebrand
et al. 2014; Keser et al. 2015; Lerma-Cabrera et al. 2016;
Meule et al. 2015; Nolan and Geliebter 2016). Based on sev-
eral findings, it seems that obesity would promote addiction to
palatable and high-calorie food (Leigh and Morris 2018; Mies
et al. 2017; Wiss et al. 2017). Whether obesity is the result of
food addiction rather than disrupted nutritional processes (in-
gestion, digestion, absorption, assimilation, digestion, and
elimination) requires further study. Moreover, if food addic-
tion is linked to psychological factors, future research should
also address the interaction between cognitive/emotional gene
activity and obesity. In addition, if gene editing is aimed at
treating obesity, we should also target changes in genes asso-
ciated with addiction (Granholm et al. 2017; Mielenz et al.
2017; Pedram et al. 2017; Rovaris et al. 2017).
Conclusion
Given that the obesity epidemic is a global public health con-
cern, and given the limited effectiveness of standard therapies
such as diet or pharmacological treatment, we believe that new
and challenging genetic approaches aimed at reducing obesity
have great potential in the coming years. Gene editing tech-
nologies coupled with knowledge of genes related to obesity
will afford new insights into the neurobiology that underlies
regulation of body weight and may lead to a breakthrough in
the prevention and treatment of obesity.
Despite the fascinating putative use of CRISPR/Cas9 for
treating obesity, some limitations should be considered.
Obesity is unlike other diseases—for example, compared to
metastatic lung cancer. Thus, one methodological challenge
would be in identifying a specific target/tissue for obesity.
Moreover, even if the mutated gene responsible for obesity
were clear, where should transgenic cells edited via
CRISPR/Cas9 be put back in the human body to treat obesity?
In these contrasting scenarios, additional elements might arise
as ethical considerations. For instance, cancer patients could
accept transgenic treatment, but perhaps few patients with
obesity would favor such treatment. Nevertheless, while the
absence of a solid body of evidence regarding the likely use of
CRISPR/Cas9 for treating obesity is quite limiting and pro-
vides a perception of weakness on the topic, it is precisely
within such a limited framework that new perspectives emerge
to represent new venues for further studies. Thus, we will
assume that in the near future, the generation of empirical
evidence derived from CRISPR/Cas9 in obese models will
be available.
Fig. 1 Proposed use of CRISPR/Cas9 technology for gene editing in
obesity. Through molecular manipulation of obesity-related genes,
CRISPR7Cas9 may represent a novel therapeutic approach for managing
obesity. Experimental genomics-based strategies would include testing
CRISPR/Cas9 editing of genes in animal models of diet-induced weight
gain
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